Literature DB >> 17010543

Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil.

Abhijit A Date1, M S Nagarsenker.   

Abstract

Self-nanoemulsifying drug delivery systems (SNEDDS) were developed with the objective to overcome problems associated with the delivery of cefpodoxime proxetil (CFP), a poorly bioavailable high dose antibiotic having pH dependant solubility. Solubility of CFP in oily phases and surfactants was determined to identify components of SNEDDS. Various surfactants and co-surfactants were screened for their ability to emulsify selected oily phases. Ternary phase diagrams were constructed to identify area of nanoemulsification for the selected systems. The influence of CFP and the pH of dilution medium on the phase behavior of selected system were assessed. The globule size of optimized CFP SNEDDS in various dissolution media was determined to check the effect of pH on its behavior. The optimized CFP SNEDDS needed surfactant content less than 40% and yielded nanoemulsion of mean globule size 170 nm, which was not affected by the pH of dilution medium. The optimized SNEDDS released CFP completely within 20 min irrespective of the pH of dissolution medium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010543     DOI: 10.1016/j.ijpharm.2006.08.038

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  51 in total

1.  The studies of phase equilibria and efficiency assessment for self-emulsifying lipid-based formulations.

Authors:  Ahmad Abdul-Wahhab Shahba; Kazi Mohsin; Fars Kaed Alanazi
Journal:  AAPS PharmSciTech       Date:  2012-03-23       Impact factor: 3.246

2.  Novel self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of cinnarizine: design, optimization, and in-vitro assessment.

Authors:  Ahmad Abdul-Wahhab Shahba; Kazi Mohsin; Fars Kaed Alanazi
Journal:  AAPS PharmSciTech       Date:  2012-07-04       Impact factor: 3.246

3.  Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis.

Authors:  Anne T Larsen; Pernilla Åkesson; Anna Juréus; Lasse Saaby; Ragheb Abu-Rmaileh; Bertil Abrahamsson; Jesper Østergaard; Anette Müllertz
Journal:  Pharm Res       Date:  2013-08-15       Impact factor: 4.200

4.  Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part I. Formulation development, statistical optimization, and in vitro characterization.

Authors:  Amit K Jain; Kaushik Thanki; Sanyog Jain
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

5.  Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS).

Authors:  Ajeet K Singh; Akash Chaurasiya; Anshumali Awasthi; Gautam Mishra; Dinesh Asati; Roop K Khar; Rama Mukherjee
Journal:  AAPS PharmSciTech       Date:  2009-07-17       Impact factor: 3.246

6.  Preparation and bioavailability assessment of SMEDDS containing valsartan.

Authors:  Adhvait R Dixit; Sadhana J Rajput; Samir G Patel
Journal:  AAPS PharmSciTech       Date:  2010-02-25       Impact factor: 3.246

7.  Product development studies on surface-adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form.

Authors:  Sumita Singh; Kamla Pathak; Vikas Bali
Journal:  AAPS PharmSciTech       Date:  2012-09-11       Impact factor: 3.246

Review 8.  Preclinical formulations: insight, strategies, and practical considerations.

Authors:  Sanket M Shah; Ankitkumar S Jain; Ritu Kaushik; Mangal S Nagarsenker; Maneesh J Nerurkar
Journal:  AAPS PharmSciTech       Date:  2014-06-12       Impact factor: 3.246

9.  Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies.

Authors:  Yogeshwar G Bachhav; Vandana B Patravale
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

10.  Design and evaluation of self-nanoemulsifying pellets of repaglinide.

Authors:  N S Desai; M S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2013-06-18       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.